2:38 PM
Jul 10, 2018
 |  BC Innovations  |  Distillery Therapeutics


INDICATION: Small cell lung cancer

Patient sample and cell culture studies suggest promoting IGFBP5 expression or inhibiting POU2F3 or IGF1R could help treat POU2F3-expressing small cell lung cancer (SCLC). In tumor samples from SCLC patients, levels of IGF1R were higher, and levels of its negative regulator IGFBP5 were lower, in tumors expressing high levels of POU2F3 than in tumors expressing low levels of POU2F3....

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD
More Info >